शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
BSECentenial Surgical Suture Ltd· Healthcare Equipment & SuppliesHighNeutral
Announced Thu, 13 Nov, 2025 · 19:31 IST

With reference to the above captioned subject, we wish to inform you that the Board of Directors at their meeting held on Thursday, November 13, 2025 approved the following: 1). Standalone ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-8.3%Reaction day
₹104.00
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-8.2% vs market
Medical Equipment & Supplies peers, median of 13sector+0.0%-8.3% vs sector

On the reaction day the stock moved 8.2 pts less than Nifty Microcap 250 and 8.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-8.3-0.1-8.2+0.0-8.3
Next day
-0.2+0.5-0.7-2.0+1.8
2d
—-0.3—-3.2—
3d
-3.8-0.5-3.4-4.0+0.1
4d
+1.8-0.8+2.6-4.3+6.1
5d
-7.7-2.3-5.4-5.2-2.5
1w
+6.8-2.8+9.6-7.2+14.0
15d
-3.5-4.9+1.4-4.0+0.5
1m
-6.4-4.7-1.7-3.8-2.6
2m
-10.4-7.7-2.6-15.1+4.8
3m
-5.8-7.8+2.1-23.7+17.9
UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Centenial Surgical Suture Ltd announced that its Board of Directors, at a meeting held on November 13, 2025 (6:00 PM to 6:25 PM), approved three items: (1) Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2025, (2) Statement of Assets and Liabilities for the half year ended September 30, 2025, and (3) Cash Flow Statement for the half year ended September 30, 2025. The filing was made under SEBI LODR Regulation 30 and 33. No specific financial figures have been disclosed in this filing — it is purely an intimation of board approval of the results documents.

Likely market impact

This is a routine compliance filing confirming the board's approval of Q2/H1 FY26 results. The actual financial numbers are not shared in this intimation and would have been filed separately; investors should look at the detailed results document to assess performance. No material strategic or structural change is indicated.